Methods of preventing, treating and diagnosing disorders of protein aggregation

Abstract

Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.

1 . A method of treating or preventing in a subject a condition of the central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence comprising administering to said subject a pharmaceutically effective amount of a compound having the following structure: 
       
         
           
           
               
               
           
         
         wherein each of R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , R 4′ , R 5 , R 5′ , R 6 , and R 6′  is independently selected from the group of: 
         (a) hydrogen atom; 
         (b) NHR 7 , wherein said R 7  is selected from the group of hydrogen; C 2 -C 10  acyl and C 1 -C 10  alkyl; 
         (c) NR 8 R 9 , wherein said R 8  is C 2 -C 10  acyl or C 1 -C 10  alkyl and said R 9  is C 2 -C 10  acyl or C 1 -C 10  alkyl; 
         (d) OR 10 , wherein said R 10  is selected from the group of no group, hydrogen, C 2 -C 10  acyl, C 1 -C 10  alkyl and SO 3 H; 
         (e) C 5 -C 7  glycosyl; 
         (f) C 3 -C 8  cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OH, NH 2 , SH, OSO 3 H and OPO 3 H 2 ; 
         (g) SR 11 , wherein R 11  is selected from the group of hydrogen, C 1 -C 10  alkyl and O 3 H; 
         (h) C 1 -C 10  alkyl optionally substituted with a substituent selected from the group of hydrogen, OR 10 , NH R7 , NR 8 R 9  and SR 11 ; and 
         (i) C 3 -C 8  cycloalkyl optionally substituted with a substituent selected from the group of hydrogen, OR 10 , NHR 7 , NR 8 , R 9  and SR 11 , 
       
       providing that the compound is not myo-inositol. 
     
     
         2 .- 201 . (canceled)